touchEXPERT BRIEFING

Updates and new guidelines in statin therapy

Clinical specialists from Europe and the USA discuss the management of cholesterol in patients with high low-density lipoprotein cholesterol (LDL-C). The importance of using a high dose of a statin is emphasized especially in patients at high risk.

The information in this activity is intended for healthcare professionals involved in the treatment of patients with high LDL-C levels.

This EXPERT BRIEFING was recorded during the ESC Congress 2019, Paris, France.

Menu

Learning Objectives

After watching this touchEXPERT BRIEFING, you should be able to:

  • Understand the importance of the ACC/AHA 2018 and ESC 2019 guidelines for management of blood cholesterol/dyslipidaemias with respect to clinical practice
  • Know the risks and benefits of statin treatment with respect to the risk for type 2 diabetes
  • Understand the potential for abnormal liver function and metabolic syndrome and be aware of drug-drug interaction as most statins are metabolized via the cytochrome P450 pathway
  • Know that the PROVE IT and REAL-CAD trials show that high-dose statin therapy is superior to moderate or low dose in cardiovascular event reduction
  • Understand that combination therapy gives an additional reduction in LDL levels and that statin dose should be titrated to risk

References

  1. Grundy SM, et al. Circulation 2018;139:e1082-1143.
  2. Mach F, et al. Eur Heart J 2019;00:178.
  3. Stone NJ, et al. J Amer Coll Cardiol 2014;63:2889-934.
  4. Catapano AL, et al. Eur Heart J 2016;37:2999-3058.
  5. Haffner SM, et al. Diabetes 1992;41:715-22.
  6. Haffner SM, et al. JAMA 1990;263: 2893-8.
  7. Sattar N, et al. Circulation 2003;108:414-9.
  8. Feeman WE. Circulation 2004;109:e23.
  9. Sattar N, et al. Lancet 2010;375:735-42.
  10. Preiss D, et al. JAMA 2011;305:2556-64.
  11. Ridker PM, et al. Lancet 2012;380:565-71.
  12. Vallejo-Vaz AJ, Atherosclerosis 2015;241:409-18.
  13. Rowan CG, et al. Pharmacoepidemiol Drug Saf 2012;21:494-506.
  14. Pitavastatin prescribing information. https://www.kowapharma.com/documents/LIVALO_PI_CURRENT.pdf
  15. Athyros VG, at al. Lancet 2010;376:1916-22.
  16. CTT collaborators. Lancet 2012;280:581-90.
  17. Mach F, et al. Eur Heart J 2020;41:111-88.
  18. Cannon CP, et al. NEJM 2015;372:2387-97.
  19. Taguchi I, et al. Circulation 2018;137:1997-2009.
  20. Giugliano RP, et al. Circulation 2018;137:1571-82.
  21. Giugliano RP, et al. Lancet 2017;390:1962-71.
  22. Boekholt SM, et al. J Am Coll Cardiol 2014;64:485-94.
  23. Sabatine MS, et al. NEJM 2017;376:1713-22.
  24. Schwartz GC, et al. NEJM 2018;379:2097-2107.

Please feedback on this touchEXPERT BRIEFING on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72